Latest From Durect Corp.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Third enforcement letter of the year cites meeting exhibit and webpage that suggest crenolanib is safe and effective for an unapproved use.
Drug Discovery Tools
- Large Molecule
- Drug Discovery Tools
- Implantable Devices
- Controlled Release
- Site Specific
- Drug Delivery
- Therapeutic Areas
- Hepatic (Liver)
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- North America
- Parent & Subsidiaries
- Durect Corp.
- Senior Management
James E Brown, DVM, Pres. & CEO
Michael H Arenberg, CFO
WeiQi Lin, MD, PhD, SVP, R&D, R&D Bus. Dev.
Robert M Janosky, VP, Strategic Planning & Bus. Dev.
- Contact Info
Phone: (408) 777-1417
10260 Bubb Rd.
Cupertino, CA 95014-4166
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.